PharmaShots | Incisive News in 3 Shots

Subscribe Now

CSL Vifor

CSL Vifor and Travere Therapeutics’ Filspari (sparsentan) Gains CHMP’s Positive Opinion to Treat IgA Nephropathy

CSL Vifor and Travere Therapeutics’ Filspari (sparsentan) Gains CHMP’s Positive Opinion to Treat IgA Nephropathy

February 23, 2024

CSL Vifor and Fresenius Kabi Receive the NMPA’s Approval for Ferinject to Treat Iron Deficiency in Adult Patients

CSL Vifor and Fresenius Kabi Receive the NMPA’s Approval for Ferinject to Treat Iron Deficiency in Adult Patients

November 29, 2022

CSL Vifor and Travere Reports the EMA’s Acceptance of Conditional Marketing Authorization Application for Review of Sparsentan to Treat IgA Nephropathy

CSL Vifor and Travere Reports the EMA’s Acceptance of Conditional Marketing Authorization Application for Review of Sparsentan to...

August 22, 2022

CSL Vifor’s Tavneos (avacopan) Receives NICE Recommendation for the Treatment of Anca-Associated Vasculitis (GPA/MPA)

CSL Vifor’s Tavneos (avacopan) Receives NICE Recommendation for the Treatment of Anca-Associated Vasculitis (GPA/MPA)

August 18, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us